News & Media
Press Releases
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism Download a PDF copy of this press release: EN FR Lyon, …
Amolyt Pharma Announces Research Collaboration with PeptiDream
Amolyt Pharma Announces Research Collaboration with PeptiDream Download a PDF copy of this press release: EN FR Amolyt and Peptidream will collaborate to optimize and …
Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism
LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed.
Presentations
- All PRESENTATIONS
- AZP-3404
- AZP-3601
- All PRESENTATIONS
- AZP-3404
- AZP-3601
Upcoming events
Date: September 29 – October 3, 2021 (Virtual)
Date: October 1-4, 2021 (Toronto)
Date: October 13-16, 2021 (Le Havre)
Date: October 19-22, 2021 (Denver, CO)
Date: November 2-7, 2021 (San Diego, CA)
Social Updates
TWITTER